Evidence map›Paper›PMID 9498536›Full record

ArticleCirculation1998

Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors.

A Nitenberg, F Paycha, S Ledoux, R Sachs, J R Attali, P Valensi

Registry-linked trialOpen access · bronzeAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Circulation, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02655770 (Influence of Liraglutide on Diastolic Cardiac Function and Myocardial Perfusion as Determined by Magnetic Resonance Imaging in Patients With Type 2 Diabetes), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02655770 phase4completedstarted 2016, after this paper: background citation

Influence of Liraglutide on Diastolic Cardiac Function and Myocardial Perfusion as Determined by Magnetic Resonance Imaging in Patients With Type 2 Diabetes: a Double-blind Randomized Parallel-group Trial

Ran2016Enrolled40Registered outcomes4Posted comparisons0ConditionsCardiac MRI, Diabetes Mellitus Type 2, Diastolic Dysfunction, Myocardial PerfusionArmsliraglutide, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 126 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes.American journal of physiology. Heart and circulatory physiology · 2011
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Noninvasive assessment of preclinical atherosclerosis.Vascular health and risk management · 2006
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

A NitenbergService de Physiologie et d'Explorations Fonctionnelles, INSERM, Hôpital Louis Mourier, CHU Xavier-Bichat, Colombes, France.
F Paycha
S Ledoux
R Sachs
J R Attali
P Valensi
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcetylcholine produces coronary artery (CA) constriction in diabetic patients, suggesting an impairment of endothelium-dependent dilation. In diabetes, multiple metabolic abnormalities may inactivate nitric oxide through oxygen free radical production. METHODS AND

resultsTo examine the mechanism of this abnormal response, two physiological tests (ie, a cold pressor test [CPT] and coronary flow increase induced by an injection of 10 mg papaverine [PAP] in the distal left anterior descending CA) were performed before and after either intravenous L-arginine (625 mg/min x 10 minutes) or intravenous deferoxamine (50 mg/min x 10 minutes) in 22 normotensive nonsmoking diabetic patients with angiographically normal CAs and normal cholesterol. Coronary surface areas were measured with quantitative angiography. Before the administration of L-arginine or deferoxamine, CPT induced CA constriction in both groups (-14 +/- 10% and -15 +/- 11%, respectively; each P<.001), and PAP injection in distal LAD did not modify significantly proximal LAD dimensions. In the 10 diabetic patients receiving L-arginine, responses to CPT and PAP were not modified. Conversely, in the 12 patients receiving deferoxamine, CA dilated in response to the two tests (+10 +/- 9% after CPT and +22 +/- 7% after PAP, each P<.001). Intracoronary isosorbide dinitrate, an endothelium-independent dilator, produced similar dilation in the two groups (+47 +/- 19% and +41 +/- 15%, respectively; each P<.001).

conclusionsThis study shows that (1) responses of angiographically normal CAs to CPT and to flow increase are impaired in diabetic patients; (2) abnormal responses are not improved by L-arginine, suggesting that a deficit in substrate for nitric oxide synthesis is not involved; and (3) deferoxamine restores a vasodilator response to the two tests, suggesting that inactivation of NO by oxygen species might be partly responsible for the impairment of CA dilation in diabetic patients.

Indexed as

AdultAntidotesArginineCold TemperatureCoronary AngiographyCoronary VesselsDeferoxamineDiabetes Mellitus, Type 2FemaleHemodynamicsHumansIron Chelating AgentsMaleMiddle AgedPapaverineRisk FactorsAntidotesArginineDeferoxamineIron Chelating AgentsPapaverineVasodilator Agents

Identifiers

PMID9498536
OpenAlexW2077130091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.